![Shirley Kleinman](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Shirley Kleinman
Plus aucun poste en cours
Historique de carrière de Shirley Kleinman
Anciens postes connus de Shirley Kleinman
Sociétés | Poste | Début | Fin |
---|---|---|---|
Notal Vision Ltd.
![]() Notal Vision Ltd. Medical/Nursing ServicesHealth Services Notal Vision Ltd. develops and manufactures computerized ophthalmic diagnostic devices. It develops age-related macular degeneration (AMD) monitor for patients at risk of vision loss from the devastating effects of wet AMD. The firm provides Preferential Hyperacuity Perimetry, a technology with clinical data for monitoring patients with AMD to eye care professionals. Its products are used for the detection and characterization of central and paracentral metamorphopsia in patients as an aid in monitoring progression of disease factors causing metamorphopsia, such as choroidal neovascularization. The company was founded in 2000 by Barak Azmon and Yair Alster and is headquartered in Tel Aviv, Israel. | Directeur Financier/CFO | - | 24/07/2017 |
Formation de Shirley Kleinman
Tel-Aviv University | Undergraduate Degree |
Instituto de Empresa SL | Masters Business Admin |
Statistiques
Internationale
Israël | 3 |
Espagne | 2 |
Opérationnelle
Director of Finance/CFO | 1 |
Undergraduate Degree | 1 |
Masters Business Admin | 1 |
Sectorielle
Consumer Services | 3 |
Health Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Notal Vision Ltd.
![]() Notal Vision Ltd. Medical/Nursing ServicesHealth Services Notal Vision Ltd. develops and manufactures computerized ophthalmic diagnostic devices. It develops age-related macular degeneration (AMD) monitor for patients at risk of vision loss from the devastating effects of wet AMD. The firm provides Preferential Hyperacuity Perimetry, a technology with clinical data for monitoring patients with AMD to eye care professionals. Its products are used for the detection and characterization of central and paracentral metamorphopsia in patients as an aid in monitoring progression of disease factors causing metamorphopsia, such as choroidal neovascularization. The company was founded in 2000 by Barak Azmon and Yair Alster and is headquartered in Tel Aviv, Israel. | Health Services |
- Bourse
- Insiders
- Shirley Kleinman
- Expérience